Table 1.
Clinical and biological characteristics of the study subjects
| T2D patients (n = 20) |
Controls (n = 25) |
P value | |
|---|---|---|---|
| Age (y) | 55.9 ± 13.4 | 48.5 ± 9.0 | 0.051 |
| Sex ratio (M/F) | 11/9 | 12/13 | |
| BMI (kg/m2) | 36.8 ± 8.1 | 22.4 ± 2.3 | < 0.00001 |
| Fasting blood glucose (mmol/L) | 9.39 ± 2.77 | 4.77 ± 0.47 | < 0.00001 |
| HbA1c (%) | 10.03 ± 2.32 | NA | |
| Metformin + sulfonylurea users | 35% | NA | |
| Metformin + insulin users | 20% | NA | |
| Sulfonylurea + insulin users | 20% | NA | |
| Metformin + sulfonylurea + insulin users | 15% | NA | |
| eGFR CKD-EPI (mL/min/1.73 m2) | 100 ± 17 | 101 ± 17 | 0.86 |
| Serum triglycerides (mmol/L) | 2.38 ± 1.01 | 0.92 ± 0.38 | <0.00001 |
| Serum total cholesterol (mmol/L) | 4.61 ± 1.07 | 5.39 ± 1.03 | 0.035 |
| Serum HDL cholesterol (mmol/L) | 1.06 ± 0.35 | 1.77 ± 0.42 | < 0.00001 |
| Serum LDL cholesterol (mmol/L) | 2.56 ± 0.82 | 3.19 ± 0.89 | 0.035 |
| Serum apoAI in fraction with d > 1.129 g/mL (g/L) | 0.62 ± 0.08 | 0.59 ± 0.11 | 0.35 |
| Serum apoAI in fraction with d < 1.129 g/mL (g/L) | 0.78 ± 0.18 | 1.10 ± 0.19 | < 0.001 |
Data are presented as mean ± SD.
Abbreviations: apoAI, apolipoprotein AI; BMI, body mass index; d, density; eGFR CKD-EPI, estimated glomerular filtration rate Chronic Kidney Disease-Epidemiology Collaboration; F, female; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, male; T2D, type 2 diabetes.